Following an impressive surge in quarterly revenues, shares of AVITA Medical, Inc. (NASDAQ: RCEL) demonstrated significant upward momentum. On Friday, RCEL stock experienced a notable increase of 20.66%, concluding the trading session at $9.57.
Record-Breaking Revenue and Expanded Market Reach
In the second quarter, AVITA Medical (RCEL) achieved a record commercial revenue of $15.1 million. This achievement underscores the effectiveness of the company’s intensified focus on commercial execution. The notable revenue growth was primarily attributed to deeper market penetration within existing customer accounts and the acquisition of new accounts, particularly for addressing full-thickness skin defects.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The company’s progress was further highlighted by the FDA approval of RECELL GO, and the recent submission of RECELL GO mini. These advancements represent significant strides in expanding treatment options for burn injuries and full-thickness skin defects.
Strategic Partnerships and Future Developments
Additionally, AVITA Medical’s partnership with Regenity Biosciences significantly broadens its clinical capabilities. This agreement will enhance the company’s ability to meet a comprehensive range of clinical needs. AVITA Medical remains committed to establishing RECELL as the standard of care for wound therapy while transitioning towards a broader wound care provider role. This strategic shift aims to improve accessibility and patient reach.
Looking ahead, AVITA Medical anticipates receiving 510(k) clearance for Regenity’s dermal matrix in the fourth quarter of 2024. Upon clearance, the company will commence marketing, selling, and distributing this new product. The company also plans to initiate multiple post-market clinical studies to explore the potential synergies between the new dermal matrix and RECELL.
Furthermore, AVITA Medical expects FDA approval for RECELL GO mini by December 27, 2024. The company aims to submit a post-market study on stable vitiligo (TONE) and a separate healthcare economics study by the end of the year. In a strategic move, AVITA Medical has entered into an exclusive multi-year development and distribution agreement with Regenity.
This partnership will provide AVITA Medical with exclusive rights to market and distribute a novel collagen-based dermal matrix, which will be manufactured by Regenity. This collaboration is poised to enhance AVITA Medical’s portfolio and align with its long-term growth objectives, potentially setting a new standard of care through integrated and innovative solutions.
